Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the… FDA label
Also known as Dalteparin sodium, Fragmin (dalteparin sodium )
Fragmin · 3 trials · 2 indications
A successful HD session is defined in terms of efficacy of the drug where the HD session had completed as planned: there was no premature termination due to Grade 3 or 4 clotting or saline flush to prevent the loss of the extracorporeal circuit due to clotting; it was not possible to return the participant's blood or assess the exact extent of clotting. HD sessions which terminated prematurely due to Grade 1 or 2 clotting, safety event, machine failure, or access site displacement were excluded from the analysis. The point estimate and 95% CI were computed based on generalized estimating equation (GEE) model for clustered binomial data.
Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 gram (g)/litre (L) (2 g/ decilitre \[dL\]), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular). Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.
Major hemorrhages: defined as fatal bleeding, clinically overt bleeding causing a fall in hemoglobin greater than or equal to 20 g/L (2 g/dL), clinically overt bleeding leading to transfusion of greater than or equal to 2 units of whole blood or red cells, or symptomatic bleeding in areas of special concern (intracranial, retroperitoneal, intraocular, intraspinal, pericardial, intramuscular with compartmental syndrome, or intraarticular).
Minor hemorrhages: defined as bleeding that did not meet the definition of major bleeding.
Clinically relevant minor (non-major) bleeding was defined as any bleeding compromising hemodynamics, leading to hospitalization, subcutaneous haematoma more than 25 cm\^2, intramuscular haematoma, epistaxis lasting for more than 5 minutes, spontaneous gingival bleeding, macroscopic hematuria and gastrointestinal hemorrhage (including at least 1 episode of melaena or hematemesis), rectal blood loss, hemoptysis, and any other bleeding with clinical consequences.
Trivial bleeding was defined as all minor bleeding that did not meet the definition of clinically relevant minor bleeding.
University of Texas (UT) system assesses ulcer depth, wound infection and clinical signs of lower-extremity ischemia. UT Wound Classification (1C/2C) was based on grade (0= healed site to 3= penetrating wound to bone or joint) and stage (A= clean wounds to D= ischaemic infected wounds) of wounds. Participants were evaluated at 4 stratums: Stratum 1: Toe pressure\>30 mm of mercury (mmHg) and UT grade and stage 1C. Stratum 2: Toe pressure\<=30 mmHg and UT grade and stage 1C. Stratum 3: Toe pressure\>30 mmHg and UT grade and stage 2C. Stratum 4: Toe pressure\<=30 mmHg and UT grade and stage 2C.
| Arm | Type | Description |
|---|---|---|
| Fragmin | EXPERIMENTAL | Fragmin given according to the flexible dosing regimen outlined in the protocol |
| Active | EXPERIMENTAL | Active study treatment |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Fragmin | DRUG | variable dosing regimen |
| Fragmin/ Dalteparin Sodium | DRUG | Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium. |
| Placebo for Fragmin/ Dalteparin Sodium | DRUG | Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium. |
Inclusion Criteria: * chronic renal failure on hemodialysis Exclusion Criteria: * significant comorbidities that would prevent a patient from completing the trial
Fragmin is a small molecule drug developed by Pfizer, Inc. (ticker PFE). It has been studied in clinical trials for chronic renal failure and diabetic foot ulcer, within the nephrology therapeutic area. Fragmin is also known by the names dalteparin sodium and dalteparin.
Fragmin has been studied for use in hemodialysis in patients with chronic renal failure. A Phase 3 trial titled Use Of Fragmin In Hemodialysis evaluated the drug in this setting in Canada, enrolling 152 participants aged 18 years and older. The trial has been completed.
Fragmin is developed by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer sponsored the clinical trials evaluating Fragmin in chronic renal failure and diabetic foot ulcer.
Fragmin has been evaluated in Phase 3 and Phase 2 clinical trials. The Phase 3 study examined Fragmin in hemodialysis for chronic renal failure, while two Phase 2 studies examined Fragmin in diabetic patients with neuroischaemic foot ulcers. All listed trials are completed.
Fragmin has been studied in completed trials including NCT01879618, a Phase 3 study of Fragmin in hemodialysis for chronic renal failure, and NCT00765063 and NCT00662831, two Phase 2 studies of Fragmin in the treatment of neuroischaemic foot ulcers in diabetic patients. Total enrollment across these trials was 338 participants.
Yes, Fragmin is also known as dalteparin sodium and dalteparin. These names refer to the same small molecule drug developed by Pfizer, Inc. (ticker PFE), which has been studied in chronic renal failure and diabetic foot ulcer.